Sabby Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Sabby Management’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-19,700	Closed	-$42K	–	226
2017 Q3	$42K	Hold	19,700	–	–	﹤0.01%	153
2017 Q2	$57K	Buy	+19,700	New	+$59.1K	﹤0.01%	201
2014 Q3	–	Sell	-5,000	Closed	-$309K	–	337
2014 Q2	$309K	Buy	5,000 +522	+12%	+$30.4K	0.01%	208
2014 Q1	$291K	Buy	+4,478	New	+$303K	0.02%	200

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

GLG LLC New York $1.39B AUM 24.01% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Sabby Management's OREX Position: Q4 2017 in Review

Sabby Management sold out of Orexigen Therapeutics, Inc. (OREX) in Q4 2017, closing a stake of 19,700 shares — an estimated $42K sold.

Sabby Management first reported a position in OREX in Q1 2014 and held it in 4 quarters. The position peaked at $309K in Q2 2014. 41 funds tracked by Wall St. Rank hold OREX as of Q4 2017.

Sabby Management reported no remaining Orexigen Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
Sabby Management sold 19,700 Orexigen Therapeutics, Inc. shares in Q4 2017, an estimated $42K.
Sabby Management first reported a position in Orexigen Therapeutics, Inc. in Q1 2014 and held it in 4 quarters.
Sabby Management's Orexigen Therapeutics, Inc. position peaked at $309K in Q2 2014.
41 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q4 2017.

Based on Sabby Management's 13F filing for Q4 2017, filed 14 Feb 2018.